Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Payables (2020 - 2025)

Bioventus' Payables history spans 6 years, with the latest figure at $10.9 million for Q4 2025.

  • For Q4 2025, Payables fell 53.87% year-over-year to $10.9 million; the TTM value through Dec 2025 reached $10.9 million, down 53.87%, while the annual FY2025 figure was $10.9 million, 53.87% down from the prior year.
  • Payables reached $10.9 million in Q4 2025 per BVS's latest filing, down from $26.6 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $41.4 million in Q3 2023 to a low of $9.9 million in Q3 2021.
  • Average Payables over 5 years is $21.6 million, with a median of $20.8 million recorded in 2022.
  • Peak YoY movement for Payables: skyrocketed 282.52% in 2021, then tumbled 53.87% in 2025.
  • A 5-year view of Payables shows it stood at $16.9 million in 2021, then surged by 116.95% to $36.7 million in 2022, then crashed by 37.22% to $23.0 million in 2023, then grew by 2.83% to $23.7 million in 2024, then crashed by 53.87% to $10.9 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Payables are $10.9 million (Q4 2025), $26.6 million (Q3 2025), and $24.2 million (Q2 2025).